Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
Equities Analysts Set Expectations for SLDB FY2025 Earnings
Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.